Posted on 02/01/2023 9:06:11 PM PST by ConservativeMind
In an internationally conducted clinical trial lead by Dana-Farber involving patients with recurrent ovarian cancer that is resistant to platinum therapy, a novel conjugate therapy called mirvetuximab soravtansine resulted in substantially better responses than standard treatments. Mirvetuximab soravtansine was granted accelerated approval November 2022.
"The results of the SORAYA study supported the accelerated FDA approval of mirvetuximab for patients with recurrent, platinum-resistant, folate receptor alpha-positive ovarian cancer," Ursula A. Matulonis, MD.
The study enrolled 106 patients with platinum-resistant high-grade serous ovarian cancer that highly expressed folate receptor alpha. The participants had been treated with up to three prior treatments for their ovarian cancer.
The study results show that after a median follow-up of 13.4 months, 32.4% of participants had an objective anti-cancer response, including five who had a complete response, or the disappearance of all signs of cancer. The median duration of response was 6.9 months.
Importantly, drug activity was observed irrespective of the number of previous lines of therapy received or PARP inhibitor exposure in patients having received prior bevacizumab. Mirvetuximab was well-tolerated by study participants. The most common adverse side effects associated with the treatment were blurred vision, keratopathy (a non-inflammatory condition of the eye), and nausea.
The novel agent is one of a growing number of antibody-drug conjugates, or ADCs, which consist of a drug linked to an antibody that directly targets the cancer cell. Mirvetuximab connects an antibody targeting the folate receptor alpha molecule on high-grade serous ovarian cancers to a drug molecule called DM4 that disrupts microtubule formation. (Microtubules are major components of the cytoskeleton that give shape and structure to cells.) The folate receptor protein is far more abundant in some tumor cells than normal cells, making it an attractive target for cancer drugs.
(Excerpt) Read more at medicalxpress.com ...
Ovarian cancer is a bad one mostly because by the time you have symptoms and it is discovered it is usually in the late stages ovarian and pancreatic are the worst!!
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.